Titan Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Titan Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative treatments for serious medical conditions. Its main product, Probuphine®, is a slow-release implant of buprenorphine hydrochloride designed to provide continuous medication for up to six months. This implant aims to improve patient compliance and reduce the risk of illicit use or accidental exposure compared to traditional oral formulations of buprenorphine. Titan has submitted a New Drug Application (NDA) to the FDA for approval to treat opioid dependence and has entered into a partnership with Braeburn Pharmaceuticals for commercialization in the U.S. and Canada. In addition, Titan is exploring the potential application of its ProNeura™ drug delivery technology for other chronic conditions, such as Parkinson's disease. The company also benefits from royalty revenue from the sale of Fanapt®, an atypical antipsychotic, through a licensing agreement with Novartis Pharma AG.
Titan Pharmaceuticals has raised $1.0M across 1 funding round on record, the most recent an undisclosed round of $1.0M announced in Apr 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Titan Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Apr 2025.
Titan Pharmaceuticals Funding Rounds
Titan Pharmaceuticals Founders and Leadership Team
Contact details for the Titan Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Titan Pharmaceuticals Funding Compared to Other Biotechnology Startups
Titan Pharmaceuticals' latest round of $1.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Titan Pharmaceuticals in Biotechnology and South San Francisco
Companies Similar to Titan Pharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Titan Pharmaceuticals Funding FAQs
What does Titan Pharmaceuticals do?
Titan Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative treatments for serious medical conditions. Its main product, Probuphine®, is a slow-release implant of buprenorphine hydrochloride designed to provide continuous medication for up to six months. This implant aims to improve patient compliance and reduce the risk of illicit use or accidental exposure compared to traditional oral formulations of buprenorphine. Titan has submitted a New Drug Application (NDA) to the FDA for approval to treat opioid dependence and has entered into a partnership with Braeburn Pharmaceuticals for commercialization in the U.S. and Canada. In addition, Titan is exploring the potential application of its ProNeura™ drug delivery technology for other chronic conditions, such as Parkinson's disease. The company also benefits from royalty revenue from the sale of Fanapt®, an atypical antipsychotic, through a licensing agreement with Novartis Pharma AG.
How much funding has Titan Pharmaceuticals raised?
Titan Pharmaceuticals has raised $1.0M across 1 round on record. The most recent is an undisclosed round of $1.0M announced in Apr 2025.
When did Titan Pharmaceuticals last raise funding?
Titan Pharmaceuticals' most recent funding round on record is an undisclosed round of $1.0M, announced in Apr 2025.
Who founded Titan Pharmaceuticals?
FundedIQ lists Sunil Bhonsle (Founder) at Titan Pharmaceuticals.
Where is Titan Pharmaceuticals headquartered?
Titan Pharmaceuticals is based in South San Francisco, California, United States.
How many employees does Titan Pharmaceuticals have?
Titan Pharmaceuticals is in the 11-50 employee band.
How does Titan Pharmaceuticals' funding compare to other Biotechnology startups?
Titan Pharmaceuticals' latest round of $1.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Titan Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Titan Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.